HIGHBuilt-in & outside partyPipeline
ersodetug
“10-K Item 1: 'Our lead clinical asset, ersodetug, is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism.'”
RZLT · Concentration risk · 10-K extracted
Rezolute (RZLT) concentration risks
Updated
The most significant concentration Rezolute discloses is ersodetug, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Rezolute’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH1
MEDIUM1
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
MEDIUMOutside partySupplier
small number of third-party suppliers
“10-K Item 1A: 'We rely upon a small number of third-party suppliers for the manufacture of certain raw materials that are necessary to formulate our drug products for preclinical and clinical testing purposes.'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Rezolute's concentration risk is centered on a single clinical asset: ersodetug, described as the company's lead clinical asset and a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism, carries a high-share, mixed-character exposure — part structural, given the company's clinical-stage focus, and part idiosyncratic, given that it names one specific drug candidate rather than a broader pipeline. Compounding that pipeline concentration is a manufacturing dependency: the company relies on a small number of third-party suppliers for raw materials needed to formulate its drug products for preclinical and clinical testing, a medium-share dependency on external counterparties. These two exposures reinforce each other — a supply disruption affecting those raw-material suppliers would directly threaten the ability to advance ersodetug specifically, since it is the asset the company is most dependent on. For an educated investor, this combination means Rezolute's near-term value is tied tightly to both clinical and regulatory execution on a single lead candidate and operational execution on a thin supplier base, with little disclosed diversification on either the pipeline or the supply side to cushion a setback in either area.
For the engine’s reasoning on RZLT’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| RZLT● | Rezolute, Inc. | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.